

CITATION REPORT

List of articles citing

Phosphodiesterase type 5 inhibitors: the day after

DOI: 10.1016/j.eururo.2006.07.020

European Urology, 2007, 51, 75-88; discussion 89.

Source: <https://exaly.com/paper-pdf/42947544/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
77	Erectile dysfunction drugs and risk of anterior ischaemic optic neuropathy: casual or causal association?. <i>British Journal of Ophthalmology</i> , 2007 , 91, 1551-5	5.5	30
76	Testosterone and Erection: Practical Management for the Patient with Erectile Dysfunction. <i>European Urology Supplements</i> , 2007 , 6, 868-873	0.9	8
75	Centrally acting mechanisms for the treatment of male sexual dysfunction. <i>Urologic Clinics of North America</i> , 2007 , 34, 483-96, v	2.9	25
74	Salvage strategies for nonresponders to phosphodiesterase-5 inhibitor treatment for erectile dysfunction in the aging male. <i>Aging Health</i> , 2007 , 3, 527-542		1
73	Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study. <i>International Journal of Clinical Practice</i> , 2007 , 61, 1850-62	2.9	27
72	When treating erectile dysfunction, do not forget the partner. <i>International Journal of Clinical Practice</i> , 2008 , 62, 6-8	2.9	4
71	Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue. <i>European Urology</i> , 2007 , 52, 495-501	10.2	30
70	Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study. <i>European Urology</i> , 2007 , 52, 1768-74	10.2	57
69	Editorial comment on: Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study. <i>European Urology</i> , 2007 , 52, 1775-6	10.2	0
68	Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. <i>European Urology</i> , 2007 , 52, 990-1005	10.2	45
67	The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: a critical analysis of basic science and clinical data. <i>European Urology</i> , 2007 , 52, 1331-9	10.2	34
66	Efficacy and safety of oral SK3530 for the treatment of erectile dysfunction in Korean men: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group clinical trial. <i>Asian Journal of Andrology</i> , 2008 , 10, 791-8	2.8	20
65	Efficacy, tolerability and satisfaction with sildenafil citrate 100-mg titration compared with continued 50-mg dose treatment in men with erectile dysfunction. <i>BJU International</i> , 2008 , 102, 1645-50 ^{5,6}		19
64	Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. <i>Diabetic Medicine</i> , 2008 , 25, 138-46	3.5	97
63	Daily treatment with sildenafil reverses endothelial dysfunction and oxidative stress in an animal model of insulin resistance. <i>European Urology</i> , 2008 , 53, 1272-80	10.2	32
62	Editorial comment on: comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study. <i>European Urology</i> , 2008 , 54, 211-2 ^{10,2}		
61	Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2008 , 5, 2160-9	1.1	61

60	Nonarteritic anterior ischemic optic neuropathy with PDE-5 inhibitors for erectile dysfunction. <i>International Journal of Impotence Research</i> , 2008 , 20, 537-43	2.3	18
59	The use of phosphodiesterase 5 inhibitors with concomitant medications. <i>Journal of Endocrinological Investigation</i> , 2008 , 31, 799-808	5.2	49
58	What is adequate management to preserve erectile function after unilateral nerve-sparing radical prostatectomy?. <i>Journal of Endourology</i> , 2008 , 22, 2029-31; discussion 2033	2.7	4
57	You'll "get viagraed:" Mexican men's preference for alternative erectile dysfunction treatment. <i>Social Science and Medicine</i> , 2009 , 68, 1759-65	5.1	20
56	Cardiovascular effects of phosphodiesterase type 5 inhibitors. <i>Journal of Sexual Medicine</i> , 2009 , 6, 658-74.1	4.1	38
55	Cavernous artery intima-media thickness: a new parameter in the diagnosis of vascular erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2009 , 6, 1117-1126	1.1	27
54	The efficacy and safety of udenafil [Zydena] for the treatment of erectile dysfunction in hypertensive men taking concomitant antihypertensive agents. <i>Journal of Sexual Medicine</i> , 2009 , 6, 3166-76	1.1	19
53	Effect of sildenafil on middle-aged sexually active males with no erectile complaints: a randomized placebo-controlled double-blind study. <i>European Urology</i> , 2009 , 55, 969-76	10.2	13
52	Editorial Comment on: Effect of Sildenafil on Middle-Aged Sexually Active Males with No Erectile Complaints: A Randomized Placebo-Controlled Double-Blind Study. <i>European Urology</i> , 2009 , 55, 976-977	10.2	0
51	Editorial comment on: Effect of sildenafil on middle-aged sexually active males with no erectile complaints: a randomized placebo-controlled double-blind study. <i>European Urology</i> , 2009 , 55, 978	10.2	
50	Evaluation of vardenafil for the treatment of subjective tinnitus: a controlled pilot study. <i>Journal of Negative Results in BioMedicine</i> , 2009 , 8, 3		21
49	Clinical and metabolic evaluation of subjects with erectile dysfunction: a review with a proposal flowchart. <i>Journal of Developmental and Physical Disabilities</i> , 2009 , 32, 198-211		37
48	Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies. <i>BJU International</i> , 2009 , 103, 1212-7	5.6	39
47	Effects of vardenafil, a phosphodiesterase type-5 inhibitor, on sphincter of Oddi motility in patients with suspected biliary sphincter of Oddi dysfunction. <i>Gastrointestinal Endoscopy</i> , 2009 , 69, 1111-6	5.2	32
46	Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. <i>European Urology</i> , 2009 , 55, 334-47	10.2	124
45	How does chronic sildenafil prevent vascular oxidative stress in insulin-resistant rats?. <i>Journal of Sexual Medicine</i> , 2010 , 7, 79-88	1.1	8
44	Double blind trial of yohimbine hydrochloride in the treatment of erection inadequacy: an update. <i>Sexual and Relationship Therapy</i> , 2010 , 25, 392-396	1.1	
43	The future is today: emerging drugs for the treatment of erectile dysfunction. <i>Expert Opinion on Emerging Drugs</i> , 2010 , 15, 467-80	3.7	61

42	Alleviation of post-radical prostatectomy cavernosal fibrosis: future directions and potential utility for PDE5 inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2011 , 20, 1305-9	5.9	11
41	Evaluation and treatment of erectile dysfunction. <i>Medical Clinics of North America</i> , 2011 , 95, 201-12	7	17
40	The effects of phosphodiesterase type 5 inhibitors on penile rigidity variables during a period with no sexual stimulation: a laboratory setting double-blind study. <i>BJU International</i> , 2011 , 107, 264-7	5.6	5
39	The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study. <i>BJU International</i> , 2011 , 107, 1274-7	5.6	24
38	The Subjective Sexual Arousal Scale for Men (SSASM): preliminary development and psychometric validation of a multidimensional measure of subjective male sexual arousal. <i>Journal of Sexual Medicine</i> , 2011 , 8, 2255-68	1.1	3
37	New therapeutic targets for the treatment of erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2011 , 8, 3271-90	1.1	11
36	Optimizing postoperative sexual function after radical prostatectomy. <i>Therapeutic Advances in Urology</i> , 2012 , 4, 347-65	3.2	12
35	Emerging tools for erectile dysfunction: a role for regenerative medicine. <i>Nature Reviews Urology</i> , 2012 , 9, 520-36	5.5	27
34	Evaluation and treatment of erectile dysfunction in the aging male: a mini-review. <i>Gerontology</i> , 2012 , 58, 3-14	5.5	53
33	Profiling characteristics of men who use phosphodiesterase type 5 inhibitors based on obtaining patterns: data from the nationwide Japanese population. <i>Journal of Sexual Medicine</i> , 2012 , 9, 1649-58	1.1	8
32	Epidemiological study of complementary and alternative medicine (CAM) use for the improvement of sexual function in young Korean men: the Korean Internet Sexuality Survey (KISS), part II. <i>Journal of Sexual Medicine</i> , 2012 , 9, 2238-47	1.1	7
31	Intracavernous administration of bone marrow mononuclear cells: a new method of treating erectile dysfunction?. <i>Journal of Translational Medicine</i> , 2013 , 11, 139	8.5	9
30	Stem-cell therapy for erectile dysfunction. <i>Arab Journal of Urology Arab Association of Urology</i> , 2013 , 11, 237-44	1.7	12
29	Synergistic effects of BAY 60-4552 and vardenafil on relaxation of corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure. <i>Journal of Sexual Medicine</i> , 2013 , 10, 1268-77	1.1	25
28	Systematic review and meta-analysis of the use of phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction following bilateral nerve-sparing radical prostatectomy. <i>PLoS ONE</i> , 2014 , 9, e91327	3.7	27
27	Adherence to phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction in long-term users: how do men use the inhibitors?. <i>Sexual Medicine</i> , 2014 , 2, 96-102	2.7	11
26	Safety and efficacy of 20 mg pentadafil in Egyptian male patients with erectile dysfunction. <i>Human Andrology</i> , 2014 , 4, 38-43	1	
25	Relevance of serum nitric oxide levels and the efficacy of selective serotonin reuptake inhibitors treatment on premature ejaculation: decreased nitric oxide is associated with premature ejaculation. <i>Andrologia</i> , 2014 , 46, 951-5	2.4	8

24	Sexual Dysfunction in Type 2 Diabetes at Diagnosis: Progression over Time and Drug and Non-Drug Correlated Factors. <i>PLoS ONE</i> , 2016 , 11, e0157915	3.7	18
23	β-Adrenergic Receptor Antagonism Improves Erectile and Cavernosal Responses in Rats With Cavernous Nerve Injury and Enhances Neurogenic Responses in Human Corpus Cavernosum From Patients With Erectile Dysfunction Secondary to Radical Prostatectomy. <i>Journal of Sexual Medicine</i> , 2016 , 13, 1844-1857	1.1	11
22	First-generation phosphodiesterase type 5 inhibitors dropout: a comprehensive review and meta-analysis. <i>Andrology</i> , 2016 , 4, 1002-1009	4.2	42
21	Erectile dysfunction. <i>Nature Reviews Disease Primers</i> , 2016 , 2, 16003	51.1	246
20	Pelvic floor muscle training for erectile dysfunction and climacturia 1 year after nerve sparing radical prostatectomy: a randomized controlled trial. <i>International Journal of Impotence Research</i> , 2016 , 28, 9-13	2.3	33
19	Additive effects of the Rho kinase inhibitor Y-27632 and vardenafil on relaxation of the corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure. <i>BJU International</i> , 2017 , 119, 325-332	5.6	12
18	EDEUS, a Real-Life Study on the Users of Phosphodiesterase Type 5 Inhibitors: Prevalence, Perceptions, and Health Care-Seeking Behavior Among European Men With a Focus on 2nd-Generation Avanafil. <i>Sexual Medicine</i> , 2018 , 6, 15-23	2.7	9
17	[Continuous use of PDE5 inhibitors in the treatment of erectile dysfunction: New insights and opportunities]. <i>Revista Internacional De Andrología</i> , 2018 , 16, 28-33	0.6	
16	Short-term pharmacological activation of Nrf2 ameliorates vascular dysfunction in aged rats and in pathological human vasculature. A potential target for therapeutic intervention. <i>Redox Biology</i> , 2019 , 26, 101271	11.3	21
15	The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue. <i>Andrology</i> , 2019 , 7, 804-817	4.2	10
14	Effect of platelet-derived growth factor-BB on gap junction and connexin43 in rat penile corpus cavernosum smooth muscle cells. <i>Andrologia</i> , 2019 , 51, e13200	2.4	5
13	Erectile dysfunction is associated with defective L-cysteine/hydrogen sulfide pathway in human corpus cavernosum and penile arteries. <i>European Journal of Pharmacology</i> , 2020 , 884, 173370	5.3	1
12	Enhanced Contribution of Orai Channels to Contractility of Human Penile Smooth Muscle in Erectile Dysfunction. <i>Journal of Sexual Medicine</i> , 2020 , 17, 881-891	1.1	3
11	Sildenafil in ophthalmology: An update. <i>Survey of Ophthalmology</i> , 2021 ,	6.1	3
10	Combination therapy with topical alprostadil and phosphodiesterase-5 inhibitors after failure of oral therapy in patients with erectile dysfunction: a prospective, two-arm, open-label, non-randomized study. <i>International Journal of Impotence Research</i> , 2021 ,	2.3	2
9	Erectile dysfunction and lower urinary tract. <i>Handbook of Experimental Pharmacology</i> , 2009 , 507-31	3.2	12
8	The SUBITO-DE study: sexual dysfunction in newly diagnosed type 2 diabetes male patients. <i>Journal of Endocrinological Investigation</i> , 2013 , 36, 864-8	5.2	20
7	Vacuum therapy prevents corporeal veno-occlusive dysfunction and penile shrinkage in a cavernosal nerve injured rat model. <i>Asian Journal of Andrology</i> , 2020 , 22, 274-279	2.8	6

6 Erectile Dysfunction: Identification, Assessment, Treatment, and Follow-Up. **2016**, 83-115

5 Erectile Dysfunction: Identification, Assessment, Treatment, and Follow-Up. **2020**, 85-118

4 Tadalafil: the evidence for its clinical potential in the treatment of pulmonary arterial hypertension. *Core Evidence*, **2008**, 2, 225-31 4.9 2

3 Efficacy of phosphodiesterase type 5 inhibitors in patients with erectile dysfunction after nerve-sparing radical prostatectomy: a systematic review and meta-analysis.. *Translational Andrology and Urology*, **2022**, 11, 124-138 2.3 1

2 Assessing the nitric oxide and asymmetric dimethylarginine levels in lifelong premature ejaculation: A prospective study. **2022**,

1 Erectile dysfunction: Is platelet-rich plasma the new frontier for treatment in patients with erectile dysfunction? A review of the existing evidence. 4, 1